Related Experiment Videos
Chronic creatine kinase elevation not associated with HMG-CoA reductase inhibitor treatment
Insights
Chronically elevated creatine kinase (CK) levels may indicate underlying renal insufficiency or prostatic carcinoma, not just statin side effects. Clinicians should consider these possibilities when CK remains high despite no signs of myositis.
Area of Science:
- Clinical Biochemistry
- Oncology
- Nephrology
Background:
- Elevated creatine kinase (CK) levels can be associated with various conditions.
- Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are commonly prescribed for hyperlipidemia.
- Monitoring CK levels is sometimes employed during HMG-CoA reductase inhibitor therapy.
Observation:
- A 64-year-old man with renal insufficiency presented with chronically elevated CK.
- Myositis was suspected due to HMG-CoA reductase inhibitor use, but no direct link was established.
- The patient was diagnosed with prostatic cancer and underwent surgery.
Findings:
- CK levels decreased post-prostatectomy, even with continued HMG-CoA reductase inhibitor treatment.
- This suggests prostatic carcinoma and renal insufficiency as potential causes for elevated CK.
- CK is a nonspecific enzyme found in various tissues.
Implications:
- Clinicians should consider non-myositis causes for elevated CK, including renal insufficiency and malignancy.
- Prostatic carcinoma and renal insufficiency may contribute to significantly high CK concentrations.
- Awareness of these associations is crucial for accurate patient monitoring and diagnosis.
Objective:
To report a case of chronically elevated creatine kinase (CK) concentration that is possibly associated with renal insufficiency and prostatic carcinoma. The goal is to raise awareness among clinicians who monitor CK concentrations in patients receiving hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors.
Case Summary:
Because of an elevated CK concentration, a 64-year-old African-American man with a history of chronic heart disease and renal insufficiency was assessed for possible myositis relating to his treatment with HMG-CoA reductase inhibitors. However, an association between the elevated enzyme concentration and drug treatment could not be clearly established. The patient was subsequently diagnosed with prostatic cancer and underwent a radical retropubic prostatectomy. The CK enzyme concentration declined following the surgery despite continuation of the drug therapy.
Discussion:
CK is relatively nonspecific because of its wide distribution in human tissues. Although several findings of elevated CK concentrations, particularly the CK-BB isoenzyme, in patients with carcinoma or chronic renal insufficiency have been documented, these may not be common knowledge among clinicians. This case report provides an example of an unusually high CK enzyme concentration that may be linked to prostatic carcinoma and renal insufficiency.
Conclusions:
It is important to be aware of different causes for CK enzyme concentration elevation, especially when it is used as a monitoring parameter during HMG-CoA reductase inhibitor treatment. In a case of persistent elevated CK enzyme concentration without evidence of myositis, renal insufficiency may be a contributing factor and malignancy must be ruled out.